AstraZeneca: $360m investment in Irish manufacturing facility
AstraZeneca has announced its intention to establish an advanced active pharmaceutical ingredient (API) manufacturing facility for small molecules near Dublin, Ireland, with a planned investment of $360m USD. The new plant reportedly will allow for late-stage development and early commercial supply, with state-of-the-art process technology and digital innovation.
Pam Cheng, executive vice president of global operations and IT, said, “The future manufacturing of APIs for our medicines includes compounds with highly complex synthesis, requiring next generation technologies and capabilities that can respond quickly and nimbly to rapidly-changing clinical and commercial needs. This significant investment will ensure the AstraZeneca supply network is fit for the future.”